cancer

Lucie Tang, senior research engineer, died Jan. 11, 2010

Gravenhorst’s new ear is repositioned during an office visit to the maxillofacial prosthetics lab.Like any 17-year-old, Emily Gravenhorst follows a routine to get ready for a day of high school. She showers, styles her hair, puts on her make-up and eats breakfast. And just before she leaves the house, she puts on her right ear. That ear was created in the maxillofacial prosthetics laboratory at the School of Medicine, where one dental specialist and one technician help patients fit back into society after disfigurement due to accident or disease.

Gravenhorst’s new ear is repositioned during an office visit to the maxillofacial prosthetics lab.Like any 17-year-old, Emily Gravenhorst follows a routine to get ready for a day of high school. She showers, styles her hair, puts on her make-up and eats breakfast. And just before she leaves the house, she puts on her right ear. That ear was created in the maxillofacial prosthetics laboratory at Washington University School of Medicine in St. Louis, where one dental specialist and one technician help patients fit back into society after disfigurement due to accident or disease.

Courtesy of the National Cancer InstituteBreast cancer cells stained brown using an antibody that recognizes malignant cellsClinical studies are proving that the genetic profile of a tumor can greatly influence its response to anticancer treatments. WUSM physician Matthew Ellis is conducting research that aims to use the genetic profile of breast tumors to guide breast cancer therapy and ultimately to find new drugs for treating the disease.

Courtesy of the National Cancer InstituteBreast cancer cells stained brown using an antibody that recognizes malignant cellsClinical studies are proving that the genetic profile of a tumor can greatly influence its response to anticancer treatments. Matthew J. Ellis, M.D., Ph.D., at Washington University School of Medicine in St. Louis, is conducting research that aims to use the genetic profile of breast tumors to guide breast cancer therapy and ultimately to find new drugs for treating the disease.

This PET scan shows high levels of an anticancer agent in the tumor.Cancer cells keep growing because they don’t react to internal signals urging them to die. Now researchers at the School of Medicine have found an efficient way to get a messenger into cancer cells that forces them to respond to death signals. And they did it using one of the most sinister pathogens around — HIV.

Researchers linked anticancer agents to a PET tracer to deliver treatment directly to tumors in mice (red and yellow shows highest amounts of tracer).Cancer cells keep growing because they don’t react to internal signals urging them to die. Now researchers at Washington University School of Medicine in St. Louis have found an efficient way to get a messenger into cancer cells that forces them to respond to death signals. And they did it using one of the most sinister pathogens around — HIV.

ColditzGraham A. Colditz, M.D., Dr.P.H., has been named the Niess-Gain Professor and associate director of Prevention and Control at the Siteman Cancer Center at the School of Medicine and Barnes-Jewish Hospital. He will have overall responsibility for overseeing research, education, and community outreach in cancer prevention sponsored by the Center.

An experimental anti-cancer regimen combined a diuretic, a Parkinson’s disease medication and a drug ordinarily used to reverse the effect of sedatives. In research conducted at the School of Medicine, the unusual mixture inhibited the growth of aggressive prostate tumors in laboratory mice.

An experimental anti-cancer regimen combined a diuretic, a Parkinson’s disease medication and a drug ordinarily used to reverse the effect of sedatives. In research conducted at Washington University School of Medicine in St. Louis, the unusual mixture inhibited the growth of aggressive prostate tumors in laboratory mice.